Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Sunitinib

First Posted Date: 2009-04-24

Last Posted Date: 2016-09-07

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 54

Registration Number: NCT00887575

Locations: 🇺🇸
Holy Cross Hospital, Ft. Lauderdale, Florida, United States
🇺🇸
Florida Cancer Specialists North, Ft. Myers, Florida, United States
🇺🇸
National Capital Clinical Research Consortium, Bethesda, Maryland, United States

and more 11 locations

A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

Phase 3

Terminated

Conditions: Endometrial Cancer

Interventions: Drug: Ixabepilone
Drug: Doxorubicin
Drug: Paclitaxel

First Posted Date: 2009-04-17

Last Posted Date: 2017-03-09

Lead Sponsor: R-Pharm

Target Recruit Count: 551

Registration Number: NCT00883116

Locations: 🇺🇸
Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States
🇺🇸
University Of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 26 locations

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Everolimus
Drug: Trastuzumab
Drug: Paclitaxel

First Posted Date: 2009-04-06

Last Posted Date: 2018-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 719

Registration Number: NCT00876395

Locations: 🇺🇸
Comprehensive Blood and Cancer Center Dept. of CBCC (2), Bakersfield, California, United States
🇺🇸
New York Oncology Hematology NYOH Amsterdam, Albany, New York, United States
🇺🇸
Texas Oncology Charles A. Sammons Cancer Ctr, Dallas, Texas, United States

and more 24 locations

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: NSCLC

Interventions: Biological: Imprime PGG Injection
Biological: Cetuximab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-04-03

Last Posted Date: 2016-11-29

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 90

Registration Number: NCT00874848

Locations: 🇺🇸
Allison Cancer Center, Midland, Texas, United States
🇩🇪
Municipal Clinic Frankfurt Hoescht, Frankfurt, Germany
🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States

and more 11 locations

Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Imprime PGG® Injection
Biological: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-04-02

Last Posted Date: 2017-03-03

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 90

Registration Number: NCT00874107

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
University of Texas Health Science Center, San Antonio, San Antonio, Texas, United States

and more 7 locations

Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer, Non-Small Cell

Interventions: Drug: pazopanib
Drug: paclitaxel

First Posted Date: 2009-03-20

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 30

Registration Number: NCT00866528

Locations: 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

Phase 2

Completed

Conditions: Germ Cell Tumors

First Posted Date: 2009-03-18

Last Posted Date: 2021-01-12

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 101

Registration Number: NCT00864318

Locations: 🇫🇷
Hopital St André, Bordeaux, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Institut Claudius Regaud, Toulouse, France

and more 8 locations

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation

Phase 2

Completed

Conditions: Carcinoma, Non-small Cell Lung

First Posted Date: 2009-03-13

Last Posted Date: 2015-12-02

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 37

Registration Number: NCT00861627

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Male Breast Carcinoma
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIA Breast Cancer AJCC v7
Triple-Negative Breast Carcinoma

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Biological: Bevacizumab
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2009-03-13

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 454

Registration Number: NCT00861705

Locations: 🇺🇸
Wellstar Kennestone Hospital, Marietta, Georgia, United States
🇺🇸
Swedish American Hospital, Rockford, Illinois, United States
🇺🇸
HaysMed, Hays, Kansas, United States

and more 441 locations

Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Paclitaxel

First Posted Date: 2009-03-04

Last Posted Date: 2010-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 36

Registration Number: NCT00855764

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy